Pionyr Immunotherapeutics’ Phase 1a Study of TREM1-targeting Antibody PY159 for the Treatment of Solid Tumors Featured at ASCO 2023
A recommended dose of 3 mg/kg of PY159 has been determined, and seven expansion cohorts in prespecified indications are currently enrolling in the Phase 1b portion of the study.
- A recommended dose of 3 mg/kg of PY159 has been determined, and seven expansion cohorts in prespecified indications are currently enrolling in the Phase 1b portion of the study.
- The study will be featured in a poster discussion session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2-6 in Chicago and virtually.
- The poster titled, “A Phase 1a Dose Escalation Study of PY159, a Monoclonal Antibody Targeting TREM1, Triggering Receptor Expressed on Myeloid Cells 1,” will be featured in a poster discussion session at the ASCO 2023 Annual Meeting at 3-4:30 pm CDT on June 3, 2023.
- The abstract is currently available on the ASCO 2023 website, and the poster will be available on the Pionyr company website here after the completion of the ASCO poster session.